炎症性肠病合并EB病毒感染的研究进展

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Inflammatory bowel disease (IBD) is a kind of chronic idiopathic inflammatory diseases, its pathogenesis is not clear. The treatments including 5-aminosalicylic acid, adrenocortical hormone, biological agents, immunosuppressor, etc. However, adrenocortical hormone and immunosuppressor increase the risk of opportunistic infection in patients.Epstein-Barr virus infection is an opportunistic infection of IBD. In recent years, the reports about EBV infection in IBD led to refractory IBD, EBV-related lymphoproliferative diseases, lymphoma, and haemophilic cell syndromewere increasing. The progress of the epidemiology, clinical features, endoscopic and histological detection and treatment of EBV infection in IBD was presented.

Key words： Inflammatory bowel disease Epstein-Barr virus Opportunistic infection Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Lian-yu
	MIAO Ying-lei

Cite this article:

ZHOU Lian-yu,MIAO Ying-lei. Research progresson inflammatory bowel disease combined with Epstein-Barr virus infection[J]. 中国当代医药, 2020, 27(26): 24-27.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I26/24

1]	Ng SC，Shi HY，Hamidi N，et al.Worldwideincidence and prevalence of inflammatory bowel disease in the 21stcentury：a systematicreview of population-based studies[J].Lancet，2018，390（10114）：2769-2778.
[2]	Hammer T，Lophaven SN，Nielsen KR，et al.Inflammatory bowel diseases in Faroese-born Danish residents and their offspring：further evidence of the dominant role of environmental factorsin IBDdevelopment[J].AlimentPharmacol Therapeuti，2017，45（8）：1107-1114.
[3]	Ng SC，Kaplan GG，Tang W，et al.Population density and risk of inflammatory bowel disease：A prospective population-based study in 13 countries or regions in Asia-Pacific[J].Am J Gastroenterol，2019，114（1）：107-115.
[4]	Longobardi T，Jacobs P，Bernstein CN.Work losses related to inflammatory bowel disease in the UnitedStates results from the National Health Interview Survey[J].Am J Gastroenterol，2003，98（5）：1064-1072.
[5]	Lo B，Vind I，Vester-Andersen MK，et al.Direct and indirect costs of inflammatory bowel disease：ten years of follow up in a Danish Population-Based inception cohort[J].JCrohns Colitis，2020，14（1）：53-63.
[6]	Park KT，Ehrlich OG，Allen JI，et al.The cost of inflammatory bowel disease：an initiative from the Crohn′s & colitis foundation[J].Inflammatory bowel diseases，2020，26（1）：1-10.
[7]	Targownik LE，Kaplan GG，Witt J，et al.Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era：Results From a Canadian Population-Based Analysis[J].Am J Gastroenterol，2020，115（1）：128-137.
[8]	Li X，Chen N，You P，et al.The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients With Inflammatory Bowel Disease[J].Digestion，2019，99（2）：126-132
[9]	Epstein MA，Achong BG，Barr YM.Virus particles in culturedlym phoblasts from burkitt′s lym phoma[J].Lancet，1964，1（7335）：702-703.
[10]	Kuehn BM.Time to hang up the white coat?Epidemiologists suggest ways to prevent clothing from spreading infection[J].JAMA，2014，311（8）：786-787.
[11]	Attygalle AD，Cabecadas J，Gaulard P，et al.Peripheral Tcelland NK-cell lymphomas and their mimics；taking a step forward-report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopa thologyandthe Society for Hematopathology[J].Histopathology，2014，64（2）：171-199.
[12]	Ciccocioppo R，Racca F，Paolucci S，et al.Human cytomeg alovirus and Epstein-Barr virus infection in inflammatory bowel disease：need for mucosal viral load measurement[J].World J Gastroenterol，2015，21（6）：1915-1926.
[13]	Lopes S，Andrade P，Conde S，et al.Looking into Enteric Virome in Patients with IBD：Defining Guilty or Innocence[J].Inflamm Bowel Dis，2017，8（23）：1278-1284.
[14]	Magro F，Santos-Antunes J，Albuquerque A，et al.Epstein-Barr virus inflammatory bowel disease-correlation with different therapeutic regimens[J].Inflamm Bowel Dis，2013，19（8）：1710-1716.
[15]	Pezhouh MK，Miller JA，Sharma R，et al.Refractory Inflammatory Bowel Disease：Is There a Role for Epstein-Barr Virus？ a case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in Situ Hybridization[J].Hum Pathol，2018，82：187-192.
[16]	Young LS，Rickinson AB.Epstein-Barr virus：40 years on[J].Nat Rev Cancer，2004，4（10）：757-768.
[17]	Yin H，Qu J，Peng Q，et al.Molecular Mechanisms of EBVdriven Cell Cycle Progression and Oncogenesis[J].Med Microbiol Immunol，2019，208（5）：573-583.
[18]	Liu R，Wang M，Zhang L，et al.The clinicopathologic features of chronic active Epstein-Barr virus infective enteritis[J].Mod Pathol，2019，32（3）：387-395.
[19]	Ciccocioppo R，Racca F，Scudeller L，et al.Differential cellular localization of Epstein-Barr Virus and human cytomega lovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease[J].Immunol Res，2016，64（1）：191-203.
[20]	Bertalot G，Villanacci V，Gramegna M，et al.Evidence of Epstein-Barr Virus Infection in Ulcerative Colitis[J].Dig Liver Dis，2001，33（7）：551-558.
[21]	Fries W，Cottone M，Cascio A.Systematic review：macrophage activation syndrome in inflammatory bowel disease[J].Aliment Pharmacol Ther，2013，37（11）：1033-1045.
[22]	Hyams JS，Dubinsky MC，Baldassano RN，et al.Infliximab not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease[J].Gastroenterology，2017，152（8）：1901-1914.
[23]	Virdis F，Tacci S，Messina F，et al.Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn′s disease[J].World J Gastrointest Surg，2013，5（11）：306-308.
[24]	N′guyen Y，Andreoletti L，Patey M，et al.Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn′s disease[J].J Clin Microbiol，2009，47（4）：1252-1254.
[25]	Juan A，Lobatón T，Tapia G，et al.Epstein-Barr virus-positive mucocutaneous ulcer in Crohn′s disease.A condition to consider in immunosuppressed IBD patients[J].Dig Liver Dis，2017，49（8）：934-937.
[26]	Hamanaka S，Nakagawa T，Ota S，et al.Immunomodulatorassociated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn′s disease[J].Clin J Gastroenterol，2019，12（4）：330-335.
[27]	Moran NR，Webster B，Lee KM，et al.Epstein Barr viruspositive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn′s disease[J].World J Gastroenterol，2015，21（19）：6072-6076.
[28]	Yajima M，Imadome K，Nakagawa A，et al.T cell-mediated control of Epstein-Barr virus infection in humanized mice[J].J Infect Dis，2009，200（10）：1611-1615.
[29]	欧阳钦，梁红亮，王玉芳，等.亚太地区炎症性肠病处理共识意见（一）[J].胃肠病学，2006，11（4）：233-238.
[30]	Rahier JF，Magro F，Abreu C，et al.Second European evidence-based consensus on the prevention，diagnosis and management of opportunistic infections in inflammatory bowel disease[J].J Crohns Colitis，2014，8（6）：443-468.
[31]	李婷，王巧民.炎症性肠病与病毒感染的关系[J].胃肠病学和肝病学杂志，2018，27（7）：813-816.